DeepDrugDiscovery unveiled an AI screening platform designed to discover blood–brain barrier–permeable autophagy enhancers for Alzheimer’s disease. The platform focuses on a core translational problem: enhancing autophagy in the brain without triggering systemic side effects. DeepDrugDiscovery combines AI-driven screening with a BBB permeability goal, aiming to identify candidates that can modulate disease-relevant pathways in the CNS. The announcement positions the tool as a mechanism-first discovery approach for neurodegenerative programs, where drug exposure in brain tissue is often the bottleneck. If validated in subsequent preclinical and clinical work, the pipeline could expand autophagy-targeting strategies with better CNS delivery and reduced off-target risk.